Edition:
India

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

3.05USD
9:33pm IST
Change (% chg)

$-0.05 (-1.61%)
Prev Close
$3.10
Open
$3.05
Day's High
$3.05
Day's Low
$3.00
Volume
19,323
Avg. Vol
77,395
52-wk High
$5.75
52-wk Low
$1.58

Select another date:

Thu, May 10 2018

BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.23

* ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Acelrx Resubmits New Drug Application For Dsuvia

* ACELRX PHARMACEUTICALS INC - EXPECTS A SIX-MONTH REVIEW BY FDA WITH A PROJECTED PDUFA DATE IN Q4 2018

BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In Medically Monitored Settings

* ACELRX RECEIVES POSITIVE CHMP OPINION FOR DZUVEO™ FOR MANAGEMENT OF ACUTE MODERATE TO SEVERE PAIN IN MEDICALLY MONITORED SETTINGS

BRIEF-Acelrx Announces Completion Of The Human Factors Study For Dsuvia And Confirms Plans To Resubmit NDA

* ACELRX ANNOUNCES COMPLETION OF THE HUMAN FACTORS STUDY FOR DSUVIA AND CONFIRMS PLANS TO RESUBMIT NDA IN Q2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-AcelRx Pharma Q4 Loss Per Share $0.20

* ACELRX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-AcelRX Plans To Resubmit The Dsuvia New Drug Application In Q2

* ACELRX ANNOUNCES RECEIPT OF TYPE A FDA MEETING MINUTES AND PLANS TO RESUBMIT THE DSUVIA NEW DRUG APPLICATION IN Q2 2018

Select another date: